A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral).

Trial Profile

A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican) and Reduced Dose of Cyclosporine A (Neoral) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic) and Standard Dose of Cyclosporine A (Neoral).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Basiliximab; Corticosteroids; Mycophenolic acid
  • Indications Cytomegalovirus infections; Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms EVERCMV
  • Most Recent Events

    • 14 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top